CORC

在结果中检索

CORC

浏览/检索结果: 共63条，第1-10条 帮助

已选(0)清除 条数/页：   排序方式：
CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: promising findings from a prospective, open-label, randomized, phase III trial 期刊论文
CANCER COMMUNICATIONS, 2019, 卷号: 39
作者:  Shi, Yuankai;  Li, Jin;  Xu, Jianming;  Sun, Yan;  Wang, Liwei
收藏  |  浏览/下载：113/0  |  提交时间：2019/12/05
Management of anlotinib-related adverse events in patients with advanced non-small cell lung cancer: Experiences in ALTER-0303. 期刊论文
Thoracic cancer, 2019, 卷号: 10, 页码: 551-556
作者:  Si Xiaoyan;  Zhang Li;  Wang Hanping;  Zhang Xiaotong;  Wang Mengzhao
收藏  |  浏览/下载：34/0  |  提交时间：2019/11/19
The impact of previous therapy strategy on the efficiency of anlotinib hydrochloride as a third-line treatment on patients with advanced non-small cell lung cancer (NSCLC): a subgroup analysis of ALTER0303 trial 期刊论文
TRANSLATIONAL LUNG CANCER RESEARCH, 2019, 卷号: 8, 期号: 5, 页码: 575-+
作者:  Wang, Lili;  He, Zhen;  Yang, Sen;  Tang, Hong;  Wu, Yufeng
收藏  |  浏览/下载：5/0  |  提交时间：2019/12/11
Tuberculosis infection and lung adenocarcinoma: Mendelian randomization and pathway analysis of genome-wide association study data from never-smoking Asian women 期刊论文
2019
作者:  Wong Jason Y Y;  Zhang Han;  Hsiung Chao A;  Shiraishi Kouya;  Yu Kai
收藏  |  浏览/下载：102/0  |  提交时间：2020/01/03
CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: promising findings from a prospective, open-label, randomized, phase I 期刊论文
2019, 卷号: 39, 期号: 1, 页码: 28
作者:  Shi, Yuankai;  Li, Jin;  Xu, Jianming;  Sun, Yan;  Wang, Liwei
收藏  |  浏览/下载：43/0  |  提交时间：2020/01/03
Management of anlotinib-related adverse events in patients with advanced non-small cell lung cancer: Experiences in ALTER-0303 期刊论文
2019, 卷号: 10, 期号: 3, 页码: 551-556
作者:  Si, Xiaoyan;  Zhang, Li;  Wang, Hanping;  Zhang, Xiaotong;  Wang, Mengzhao
收藏  |  浏览/下载：13/0  |  提交时间：2020/01/03
Prognostic factors of refractory NSCLC patients receiving anlotinib hydrochloride as the third- or further-line treatment 期刊论文
CANCER BIOLOGY & MEDICINE, 2018, 卷号: 15, 期号: 4
作者:  Wang, Jing;  Zhao, Yizhuo;  Wang, Qiming;  Zhang, Li;  Shi, Jianhua
收藏  |  浏览/下载：3/0  |  提交时间：2019/12/04
Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer The ALTER 0303 Phase 3 Randomized Clinical Trial 期刊论文
JAMA ONCOLOGY, 2018, 卷号: 4, 期号: 11
作者:  Han, Baohui;  Li, Kai;  Wang, Qiming;  Zhang, Li;  Shi, Jianhua
收藏  |  浏览/下载：3/0  |  提交时间：2019/12/04
Phase III study of dulanermin (recombinant human tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand) combined with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer 期刊论文
INVESTIGATIONAL NEW DRUGS, 2018, 卷号: 36, 期号: 2
作者:  Ouyang, Xuenong;  Shi, Meiqi;  Jie, Fangwei;  Bai, Yuxian;  Shen, Peng
收藏  |  浏览/下载：28/0  |  提交时间：2019/12/05
Early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort study (vol 10, 153, 2017) 期刊论文
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2018, 卷号: 11
作者:  Liu, Xinyang;  Qin, Shukui;  Wang, Zhichao;  Xu, Jianming;  Xiong, Jianping
收藏  |  浏览/下载：14/0  |  提交时间：2019/12/05

©版权所有 ©2017 CSpace - Powered by CSpace